Crossmark

Favipiravir, an antiviral drug, in combination with tamoxifen exerts synergistic effect in tamoxifen-resistant breast cancer cells via hTERT inhibition

Crossref DOI link: https://doi.org/10.1038/s41598-024-51977-w

Published Online: 2024-01-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fahim, Sally A. https://orcid.org/0000-0002-7934-5030
ElZohairy, Yehia A.

Moustafa, Rehab I.
Funding

Funding for this research was provided by:

New Giza University
License Information

Text and Data Mining valid from 2024-01-22

Version of Record valid from 2024-01-22
More Information

Article History

Received: 8 May 2022

Accepted: 10 January 2024

First Online: 22 January 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below